Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actavis, Watson divest products and candidates to Par to satisfy merger conditions

Executive Summary

To satisfy FTC conditions associated with Watson Pharmaceuticals Inc.’s $5.6bn purchase of privately held generics firm Actavis Group, the two companies have agreed to divest a total of 14 generics (marketed products, pending ANDAs, and a development project) to Par Pharmaceutical Cos. Inc., which paid an undisclosed sum in cash.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase

Related Companies